Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
for Non-Muscle Invasive Bladder Urothelial Carcinoma
131 locations incl. Fayetteville
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06770582·Phase 2·Recruiting